These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
462 related articles for article (PubMed ID: 36809847)
1. Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTD. Afroz T; Chevalier E; Audrain M; Dumayne C; Ziehm T; Moser R; Egesipe AL; Mottier L; Ratnam M; Neumann M; Havas D; Ollier R; Piorkowska K; Chauhan M; Silva AB; Thapa S; Stöhr J; Bavdek A; Eligert V; Adolfsson O; Nelson PT; Porta S; Lee VM; Pfeifer A; Kosco-Vilbois M; Seredenina T Neurobiol Dis; 2023 Apr; 179():106050. PubMed ID: 36809847 [TBL] [Abstract][Full Text] [Related]
2. Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Murray ME; DeJesus-Hernandez M; Rutherford NJ; Baker M; Duara R; Graff-Radford NR; Wszolek ZK; Ferman TJ; Josephs KA; Boylan KB; Rademakers R; Dickson DW Acta Neuropathol; 2011 Dec; 122(6):673-90. PubMed ID: 22083254 [TBL] [Abstract][Full Text] [Related]
3. Targeting the TDP-43 low complexity domain blocks spreading of pathology in a mouse model of ALS/FTD. Chevalier E; Audrain M; Ratnam M; Ollier R; Fuchs A; Piorkowska K; Pfeifer A; Kosco-Vilbois M; Seredenina T; Afroz T Acta Neuropathol Commun; 2024 Oct; 12(1):156. PubMed ID: 39363348 [TBL] [Abstract][Full Text] [Related]
4. Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis. Root J; Merino P; Nuckols A; Johnson M; Kukar T Neurobiol Dis; 2021 Jul; 154():105360. PubMed ID: 33812000 [TBL] [Abstract][Full Text] [Related]
5. Genetic and immunopathological analysis of CHCHD10 in Australian amyotrophic lateral sclerosis and frontotemporal dementia and transgenic TDP-43 mice. McCann EP; Fifita JA; Grima N; Galper J; Mehta P; Freckleton SE; Zhang KY; Henden L; Hogan AL; Chan Moi Fat S; Wu SS; Jagaraj CJ; Berning BA; Williams KL; Twine NA; Bauer D; Piguet O; Hodges J; Kwok JBJ; Halliday GM; Kiernan MC; Atkin J; Rowe DB; Nicholson GA; Walker AK; Blair IP; Yang S J Neurol Neurosurg Psychiatry; 2020 Feb; 91(2):162-171. PubMed ID: 31690696 [TBL] [Abstract][Full Text] [Related]
6. TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia. Montalbano M; McAllen S; Cascio FL; Sengupta U; Garcia S; Bhatt N; Ellsworth A; Heidelman EA; Johnson OD; Doskocil S; Kayed R Neurobiol Dis; 2020 Dec; 146():105130. PubMed ID: 33065281 [TBL] [Abstract][Full Text] [Related]
7. Clinical and neuropathological features of ALS/FTD with TIA1 mutations. Hirsch-Reinshagen V; Pottier C; Nicholson AM; Baker M; Hsiung GR; Krieger C; Sengdy P; Boylan KB; Dickson DW; Mesulam M; Weintraub S; Bigio E; Zinman L; Keith J; Rogaeva E; Zivkovic SA; Lacomis D; Taylor JP; Rademakers R; Mackenzie IRA Acta Neuropathol Commun; 2017 Dec; 5(1):96. PubMed ID: 29216908 [TBL] [Abstract][Full Text] [Related]
8. Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration. Riku Y; Iwasaki Y; Ishigaki S; Akagi A; Hasegawa M; Nishioka K; Li Y; Riku M; Ikeuchi T; Fujioka Y; Miyahara H; Sone J; Hattori N; Yoshida M; Katsuno M; Sobue G Brain; 2022 Aug; 145(8):2769-2784. PubMed ID: 35274674 [TBL] [Abstract][Full Text] [Related]
9. Selective Genetic Overlap Between Amyotrophic Lateral Sclerosis and Diseases of the Frontotemporal Dementia Spectrum. Karch CM; Wen N; Fan CC; Yokoyama JS; Kouri N; Ross OA; Höglinger G; Müller U; Ferrari R; Hardy J; Schellenberg GD; Sleiman PM; Momeni P; Hess CP; Miller BL; Sharma M; Van Deerlin V; Smeland OB; Andreassen OA; Dale AM; Desikan RS; JAMA Neurol; 2018 Jul; 75(7):860-875. PubMed ID: 29630712 [TBL] [Abstract][Full Text] [Related]
10. Defective cyclophilin A induces TDP-43 proteinopathy: implications for amyotrophic lateral sclerosis and frontotemporal dementia. Pasetto L; Grassano M; Pozzi S; Luotti S; Sammali E; Migazzi A; Basso M; Spagnolli G; Biasini E; Micotti E; Cerovic M; Carli M; Forloni G; De Marco G; Manera U; Moglia C; Mora G; Traynor BJ; Chiò A; Calvo A; Bonetto V Brain; 2021 Dec; 144(12):3710-3726. PubMed ID: 34972208 [TBL] [Abstract][Full Text] [Related]
11. Targeting 14-3-3θ-mediated TDP-43 pathology in amyotrophic lateral sclerosis and frontotemporal dementia mice. Ke YD; van Hummel A; Au C; Chan G; Lee WS; van der Hoven J; Przybyla M; Deng Y; Sabale M; Morey N; Bertz J; Feiten A; Ippati S; Stevens CH; Yang S; Gladbach A; Haass NK; Kril JJ; Blair IP; Delerue F; Ittner LM Neuron; 2024 Apr; 112(8):1249-1264.e8. PubMed ID: 38366598 [TBL] [Abstract][Full Text] [Related]
12. Novel data-driven subtypes and stages of brain atrophy in the ALS-FTD spectrum. Shen T; Vogel JW; Duda J; Phillips JS; Cook PA; Gee J; Elman L; Quinn C; Amado DA; Baer M; Massimo L; Grossman M; Irwin DJ; McMillan CT Transl Neurodegener; 2023 Dec; 12(1):57. PubMed ID: 38062485 [TBL] [Abstract][Full Text] [Related]
13. C-terminal frameshift variant of TDP-43 with pronounced aggregation-propensity causes rimmed vacuole myopathy but not ALS/FTD. Ervilha Pereira P; Schuermans N; Meylemans A; LeBlanc P; Versluys L; Copley KE; Rubien JD; Altheimer C; Peetermans M; Debackere E; Vanakker O; Janssens S; Baets J; Verhoeven K; Lammens M; Symoens S; De Paepe B; Barmada SJ; Shorter J; De Bleecker JL; Bogaert E; Dermaut B Acta Neuropathol; 2023 Jun; 145(6):793-814. PubMed ID: 37000196 [TBL] [Abstract][Full Text] [Related]
14. Cracking the cryptic code in amyotrophic lateral sclerosis and frontotemporal dementia: Towards therapeutic targets and biomarkers. Akiyama T; Koike Y; Petrucelli L; Gitler AD Clin Transl Med; 2022 May; 12(5):e818. PubMed ID: 35567447 [TBL] [Abstract][Full Text] [Related]
15. Early activation of cellular stress and death pathways caused by cytoplasmic TDP-43 in the rNLS8 mouse model of ALS and FTD. Luan W; Wright AL; Brown-Wright H; Le S; San Gil R; Madrid San Martin L; Ling K; Jafar-Nejad P; Rigo F; Walker AK Mol Psychiatry; 2023 Jun; 28(6):2445-2461. PubMed ID: 37012334 [TBL] [Abstract][Full Text] [Related]
16. A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. Umoh ME; Dammer EB; Dai J; Duong DM; Lah JJ; Levey AI; Gearing M; Glass JD; Seyfried NT EMBO Mol Med; 2018 Jan; 10(1):48-62. PubMed ID: 29191947 [TBL] [Abstract][Full Text] [Related]
17. Serum naturally occurring anti-TDP-43 auto-antibodies are increased in amyotrophic lateral sclerosis. Conti E; Sala G; Diamanti S; Casati M; Lunetta C; Gerardi F; Tarlarini C; Mosca L; Riva N; Falzone Y; Filippi M; Appollonio I; Ferrarese C; Tremolizzo L Sci Rep; 2021 Jan; 11(1):1978. PubMed ID: 33479441 [TBL] [Abstract][Full Text] [Related]
18. Als and Ftd: Insights into the disease mechanisms and therapeutic targets. Liscic RM Eur J Pharmacol; 2017 Dec; 817():2-6. PubMed ID: 29031901 [TBL] [Abstract][Full Text] [Related]